Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation
This study is currently recruiting participants.
Verified June 2013 by National Institutes of Health Clinical Center (CC)
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
First received: March 13, 2010
Last updated: February 19, 2014
Last verified: June 2013
- Allogeneic hematopoietic stem cell transplantation (alloHSCT) is a procedure that transplants bone marrow cells (stem cells) from a matching donor into a recipient in order to allow the donor stem cells to produce cells that will attack the recipient s cancer cells. AlloHSCT is performed when chemotherapy, immunotherapy, or radiation therapy do not adequately control cancer growth. However, cancers that are not controlled by alloHSCT frequently become resistant to other standard treatment options.
- The outcomes of alloHSCT might be improved if certain kinds of white blood cells (T cells) could be manipulated so that they generate a more potent effect against the cancer cells. This effect can be augmented by genetically engineering donor T cells to specifically recognize cancerous cells in order to attack them. For this purpose, researchers are studying a specific kind of genetically engineered T cell known as the anti-CD19-CAR-transduced T cell. More research is needed to determine if this T cell will be an effective treatment for certain kinds of B cell cancer (such as non-Hodgkin s lymphoma and chronic lymphocytic leukemia) that has not been controlled with alloHSCT.
- To assess the safety and effectiveness of administering allogeneic anti-CD19-CAR-transduced T cells to patients with B-cell cancer that has not responded to alloHSCT.
- Individuals between 18 and 75 years of age who have received allogeneic hematopoietic stem cell transplantation for a B cell cancer, but whose cancer has either not responded to or recurred after the transplant.
- Recipients must have the same stem cell donor from their previous procedure.
- Before the start of the study, all participants will be screened with a medical history and blood tests. Recipients will have tumor imaging scans, additional blood tests, and other tests as directed by the study doctors.
- Donor participants will undergo apheresis to provide white blood cells for researchers to use in the treatment.
- Recipients will have dose escalation to determine the most effective yet safe dose of anti-CD19 T cells. There will be four dose levels of anti-CD19 T cells. The first patients enrolled will have the smallest dose, and the dose will be increased when a level has been determined to be safe. To reduce the risk of side effects, participants who received a stem cell transplant from an unrelated donor will receive a lower dose of anti-CD19 T cells than those who received a transplant from a related donor.
- Recipients will be hospitalized for 3 days after receiving the cell infusion, and will need to come to clinic for follow-up visits 1, 2, 3, 4, 8, and 12 weeks after the infusion.
- Additional scans and frequent blood tests will be required for the first 3 months after the infusion, followed by less frequent visits over time.
- Recipients will be followed for a maximum of 15 years after receiving the infusion.
B Cell Malignancies
Genetic: Anti-CD19-CAR-transduced T cells
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
||Administration of Anti-CD19-Chimeric-Antigen-Receptor-Transduced T-cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-Cell Malignancies After Allogeneic Stem Cell Transplantation
Primary Outcome Measures:
- To assess the safety of administering allogeneic anti-CD19-CAR-transduced T cells to patients with B-cell malignancies that are persistent or relapsed after alloHSCT. The allo anti-CD19-CAR transduced T cells will be derived from the original d...
Secondary Outcome Measures:
- To determine if administering anti -CD19-CAR transduced T cells can cause regression of B-cell malignancies that are relapsed or persistent after alloHSCT. To measure persistence of anti-CD19-CAR transduced T cells in the blood of patients.
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Estimated Primary Completion Date:
||October 2014 (Final data collection date for primary outcome measure)
Genetic: Anti-CD19-CAR-transduced T cells
|Ages Eligible for Study:
||18 Years to 75 Years
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
Inclusion Criteria: Recipient
Recipients (patients with B-cell malignancy) must have received an HLA-identical sibling allogeneic hematopoietic stem cell transplant, a 1-antigen mismatched related transplant, or a greater than or equal to 7/8-matched unrelated donor (URD) alloHSCT for any CD19+ B-cell malignancy. Patients with any CD19+ B-cell malignancy that is persistent or relapsed after all of the following interventions are eligible:
- Donor T cell engraftment after alloHSCT (> 50% donor chimerism of the T cell compartment and a circulating T cell population for at least 12 weeks).
- A trial of withdrawal of immunosuppressive therapy.
- At least one donor lymphocyte infusion (DLI) with a minimum T cell dose of 1 times 10(7) CD3+ cells/kg in the case of HLA-identical sibling transplants and 1-antigen mismatched related transplants or 1 times 10(6) CD3+ cells/kg in the case of greater than or equal to 7/8-matched HLA-matched URD transplants.
Only patients with ALL are eligible after full-donor T cell engraftment and a trial of withdraw of immunosuppression. Prior DLI is not an eligibility requirement for patients with ALL.
At least 4 weeks must have elapsed since the latest trial of withdraw of immunosuppression or DLI until the patient can be deemed to have persistent disease.
- CD19 expression must be detected on the majority of the malignant cells by immunohistochemistry or by flow cytometry in the Laboratory of Pathology, CCR, NCI, NIH. Definition of which cells are malignant must be determined for each patient by the Laboratory of Pathology using techniques to demonstrate monoclonality such as kappa/lambda restriction (other techniques can be used to determine monoclonality at the discretion of the Laboratory of Pathology). The choice of whether to use flow cytometry or immuohistochemistry will be determined by what is the most easily available tissue sample in each patient. Immunohistochemistry will be used for lymph node biopsies and bone marrow biopsies. Flow cytometry will be used for peripheral blood, fine needle aspirate, and bone marrow aspirate samples.
- Patients must be 18-75 years of age.
- Performance status: ECOG less than or equal to 2 (Karnofsky performance status greater than or equal to 60%)
- Life expectancy greater than or equal to 3 months.
- Either no evidence of GVHD or minimal clinical evidence of acute GVHD and chronic GVHD while off of systemic immunosuppressive therapy for at least 28 days. Minimal clinical evidence of acute GVHD is defined as grade 0 to I acute GVHD. Minimal evidence of chronic GVHD is defined as mild global score chronic GVHD (as defined by the 2005 NIH consensus project) or no chronic GVHD. Subjects with disease that is controlled to stage I acute GVHD or to mild global score chronic GVHD with local therapy only, e.g., topical cutaneous steroids or oral budesonide, will be eligible for enrollment.
- Provision for a Durable Power of Attorney.
- Ability to give informed consent.
- Prior Therapy: Therapy with monoclonal antibodies and/or chemotherapy must be stopped at least 7 days prior to anti-CD19 CAR-transduced T cell infusion, and recovery of treatment-associated toxicity to < grade 2 is required prior to infusion of cells. For patients that have received prior DLI, the last dose must be at least 28 days prior to anti-CD19 CAR-transduced T cell administration. Note that patients can be enrolled on this study at any time after or during therapy, but at least 14 days must elapse from the time of prior monoclonal antibody administration or chemotherapy until anti-CD19 CAR-transduced T cells are infused, and at least 28 days must elapse from the time of withdraw of immunosuppression or DLI until anti-CD19 CAR-transduced T cells are infused. Systemic immunosuppression must be stopped at least 28 days prior to protocol entry. There is no time restriction in regard to prior intrathecal chemotherapy provided there is complete recovery from any acute toxic effects of such.
- Recipients of unrelated donor transplants from a National Marrow Donor Program (NMDP) Center must sign a release of information form to authorize NMDP transfer of information to the NIH.
- Previous allogeneic donor must be willing and available to donate again.
- Patients of childbearing or child-fathering potential must be willing use an effective method of contraception while being treated on this study and for 4 months after the last cell infusion.
- Normal left ventricular function as evaluated by echocardiograph within 6 weeks of anti- CD19-CAR-transduced T cell infusion
Inclusion Criteria: Donor
- Donors greater than or equal to 18 years of age must be the same individual whose cells were used as the source for the patient s original stem cell transplant.
- Adequate venous access for peripheral leukapheresis, or consent to use a temporary central venous catheter for leukapheresis.
- Donors must be HIV negative, hepatitis B surface antigen negative, and hepatitis C antibody negative.
- Ability to give informed consent.
- Donor selection will be in accordance with NIH/CC Department of Transfusion Medicine (DTM) criteria and, in the case of an unrelated donor from a Transplant Center, the National Marrow Donor Program (NMDP) standards. When a potentially eligible recipient of an unrelated donor product from an NMDP Center is identified, the recipient will complete an NMDP search transfer request to allow NIH NMDP staff to contact the NMDP Coordinating Center, who will, in turn, contact the donor s prior Donor Center. The NMDP Policy for Subsequent Donation Requests will be followed and the appropriate forms (Subsequent Donation Request form) and Therapeutic T Cell Collection Prescription will be submitted as required.
Exclusion Criteria: Recipients
- Active infection that is not responding to antimicrobial therapy.
- Evidence of infection with HIV, Hepatitis B or Hepatitis C. Patients must be HIV negative, Hepatitis B surface antigen, and Hepatitis C antibody negative. The high degree of immune suppression that may be used in this study may lead to the activation or progression of these viral illnesses.
- Active psychiatric disorder which may compromise compliance with the treatment protocol, or which does not allow for appropriate informed consent (as determined by Principal Investigator and/or his designee).
- Pregnant or lactating. The effects of the immunosuppressive medications that could be required to treat GHVD are likely to be harmful to a fetus. The effects upon breast milk are also unknown and may be harmful to an infant.
- Serum total bilirubin > 2.5 mg/dl, serum ALT and AST values greater than or equal to 2.5 times the upper limit of normal based on age-specific normal values. If the abnormal liver function is attributable to liver involvement by malignancy, patients may be eligible with serum total bilirubin up to 5.0 mg/dl, and serum ALT and AST values up to 5.0 times the upper limit of normal, provided the patient has no evidence of impending hepatic failure (encephalopathy or prothrombin time > 2 times the upper limit of normal).
- Absolute neutrophil count of less than 500 cells/microL unless low neutrophil count is thought to be due to malignancy in the bone marrow and malignancy is documented in the bone marrow.
- Active cerebrospinal fluid involvement with malignancy or brain metastasis.
- Platelet count less than 10,000/microL unless low platelet count is thought to be due to malignancy in the bone marrow and malignancy is documented in the bone marrow.
- Anemia (Hb < 9 gm/dl) that cannot be corrected with transfusion. It is not atypical to have recipients with Hb levels < 9 gm/dl following transplantation, due to multiple factors (e.g. medications, low serum erythropoietin levels, etc.). As such, recipients with Hb < 9 gm/dl will be eligible if Hb can be increased and sustained (> 7days) with transfusion and the case is individually approved by the NIH Blood Bank. All patients with Hb < 9 gm/dl will undergo full evaluation for anemia.
- Receiving corticosteroids above physiological dosing within 28 days prior to anti-CD19-CAR-transduced T cell administration.
Exclusion Criteria: Donors
- History of psychiatric disorder which may compromise compliance with this protocol or which does not allow for appropriate informed consent.
- History of hypertension that is not controlled by medication, stroke, or severe heart disease (donors with symptomatic angina will be excluded). Donors with a history of coronary artery bypass grafting or angioplasty who are symptom free will receive a cardiology evaluation and be considered on a case-by-case basis.
- Donors must not be pregnant.
- Anemia (Hb < 11 gm/dl) or thrombocytopenia (platelets < 100,000 per microL). However, potential donors with Hb levels < 11 gm/dl that is due to iron deficiency will be eligible as long as the donor is initiated on iron replacement therapy. The NIH Clinical Center, Department of Transfusion Medicine/NMDP physicians will determine the appropriateness of individuals as donors.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01087294
|National Institutes of Health Clinical Center, 9000 Rockville Pike
|Bethesda, Maryland, United States, 20892 |
|Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office (888) NCI-1937 |
||James N Kochenderfer, M.D.
||National Cancer Institute (NCI)
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith GM, Parker A, Schey S, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S. Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma. Blood. 2004 Dec 15;104(13):3865-71. Epub 2004 Aug 10.
Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M, McSweeney P, Radich JP, Bredeson C, Bruno B, Langston A, Loken MR, Al-Ali H, Blume KG, Storb R, Maloney DG. Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia. J Clin Oncol. 2005 Jun 1;23(16):3819-29. Epub 2005 Apr 4.
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Kochenderfer JN, Dudley ME, Carpenter RO, Kassim SH, Rose JJ, Telford WG, Hakim FT, Halverson DC, Fowler DH, Hardy NM, Mato AR, Hickstein DD, Gea-Banacloche JC, Pavletic SZ, Sportes C, Maric I, Feldman SA, Hansen BG, Wilder JS, Blacklock-Schuver B, Jena B, Bishop MR, Gress RE, Rosenberg SA. Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation. Blood. 2013 Dec 12;122(25):4129-39. doi: 10.1182/blood-2013-08-519413. Epub 2013 Sep 20.
||National Institutes of Health Clinical Center (CC) ( National Cancer Institute (NCI) )
History of Changes
|Other Study ID Numbers:
|Study First Received:
||March 13, 2010
||February 19, 2014
||United States: Federal Government
Keywords provided by National Institutes of Health Clinical Center (CC):
Adoptive T Cell Therapy
Allogeneic Stem Cell Transplantation
B Cell Cancer
Allogenic Stem Cell Transplant
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on March 05, 2014